Evidence map›Paper›PMID 41322312›Full record

ArticleFrontiers in pharmacology2025

Correction: The active constituent of pine needle oil, bornyl acetate, suppresses NSCLC progression by inhibiting the PI3K/AKT/ABCB1 signaling axis.

Jieheng Wu, Jiaming Ren, Lu Wang, Zeyang Yang, Xuanyin Wang, Ziyi Tu, Xinlei Liu, Ye Wang, Yaxuan Cao, Xu Zhu and 5 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Jieheng Wu *Department of Immunology, Guizhou Medical University, Guiyang, China.
Jiaming Ren *Department of Immunology, Guizhou Medical University, Guiyang, China.
Lu Wang *Department of Immunology, Guizhou Medical University, Guiyang, China.
Zeyang YangDepartment of Immunology, Guizhou Medical University, Guiyang, China.
Xuanyin WangDepartment of Immunology, Guizhou Medical University, Guiyang, China.
Ziyi TuDepartment of Immunology, Guizhou Medical University, Guiyang, China.
Xinlei LiuDepartment of Anatomy, Guizhou Medical University, Guiyang, China.
Ye WangDepartment of Nursing, Guiyang Healthcare Vocational University, Guiyang, China.
Yaxuan CaoSchool of Clinical Medicine, Guizhou Medical University, Guiyang, China.
Xu ZhuDepartment of Immunology, Guizhou Medical University, Guiyang, China.
Long LiDepartment of Immunology, Guizhou Medical University, Guiyang, China.
Maoqin LuDepartment of Immunology, Guizhou Medical University, Guiyang, China.
Ying ZhangDepartment of Immunology, Guizhou Medical University, Guiyang, China.
Jinyi WuSchool of Public Health, the key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, Guizhou Medical University, Guiyang, China.
Yu CaoSchool of Public Health, the key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, Guizhou Medical University, Guiyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fphar.2025.1653461.].

Indexed as

ABCB1bornyl acetateNSCLCPI3K/AKTtumor progression

Identifiers

PMID41322312
PMCPMC12658327

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.